Clinical Trials Browser

Phase 1 × PM 01183 × Clear all

NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms

NCT05072106 2025-09-16

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Phase 1 Completed

11 enrolled 26 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05063318 2025-09-02

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Phase 1 Completed

14 enrolled 20 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04638491 2024-06-10

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Phase 1 Completed

69 enrolled 17 charts

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Phase 1 Completed

122 enrolled 19 charts

Neoplasms, Neuroendocrine Tumors

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01405391 2016-01-15

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Phase 1 Completed

GastrointestinalOther solid neoplasm

Major Advanced Solid Tumors Other Than Colorectal

NCT01314599 2015-11-05

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Phase 1 Completed

Other hematologic neoplasm

Leukemia

NCT00877474 2015-11-04

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

ADVANCED SOLID TUMORS

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Phase 1 Completed

Neoplasms